Glp-1 weight loss denied for missing prior authorization by Cigna?

Cigna's commercial coverage policy IP0206 targets liraglutide (Saxenda, generic), Wegovy, and Zepbound for chronic weight management and requires prior authorization. For adult initial therapy, the patient must have a BMI ≥ 30 kg/m² (obesity), or a BMI exceeding 30 or a comorbid condition, such as diabetes or hypertension, with a BMI over 27 ; recognized weight-related comorbidities include hypertension, Type 2 diabetes, dyslipidemia (high cholesterol), obstructive sleep apnea, or cardiovascular disease . Pediatric criteria require BMI ≥ 95th percentile for age and sex . Initial approval durations differ by product: approve for 4 months for Saxenda initial therapy , approve for 7 months of Wegovy initial therapy , and approve for 8 months of Zepbound initial therapy , with 1-year reauthorization contingent on continued therapy and demonstrated weight-loss response. For continuation, response to pharmacologic therapy should be assessed after 3 months on a therapeutic dose; if treatment has not resulted in ≥ 5% weight loss, longer-term efficacy will not likely be sufficient and a change is recommended; individuals with weight reduction ≥ 5% should continue with their current treatment . Additional MACE-reduction coverage exists for Wegovy in adults with established cardiovascular disease with overweight or obesity (e.g., prior MI, stroke, or symptomatic peripheral arterial disease), and Wegovy for MASH/NASH must be prescribed by or in consultation with a physician who specializes in the condition being treated ; Wegovy is not indicated in patients with cirrhotic (F4) MASH . Combined use with another GLP-1 or GLP-1/GIP agonist is not approved, and quantity limits restrict claims to one GLP-1 agonist at a time.

- For BMI/comorbidity denials: cite FDA labeling and AACE/Obesity Society guidelines supporting pharmacotherapy at BMI ≥ 30 or ≥ 27 with comorbidities; submit chart documentation of measured BMI and ICD-10-coded comorbidity (HTN, T2DM E11, OSA G47.33, dyslipidemia E78). - For lifestyle-modification denials: provide documented participation in a structured reduced-calorie diet, physical activity, and behavioral counseling, consistent with the policy's own framework that treatment is to address complications and diseases, not solely to reduce BMI, and the choice of pharmacotherapy is based on obesity-related comorbidities ; reference the STEP and SURMOUNT trial protocols which paired drug therapy with lifestyle intervention. - For inadequate-response denials at reauthorization: provide weighed clinic measurements showing ≥ 5% loss; note the policy itself acknowledges patients who achieve ≥ 15% weight loss (the average observed with Wegovy and Zepbound) achieve a response that predictably prevents or improves a wide range of complications — supported by STEP 1 (Wilding NEJM 2021) and SURMOUNT-1 (Jastreboff NEJM 2022). - For cardiovascular indication denials on Wegovy: cite the SELECT trial (Lincoff NEJM 2023) showing 20% MACE reduction; per policy, established cardiovascular disease with overweight or obesity is approvable with documentation of prior MI, stroke, or symptomatic PAD. - For OSA-related denials on Zepbound: cite SURMOUNT-OSA results referenced in the policy itself — in both trials, Zepbound was superior to placebo for the primary endpoint; in Trial 1, the change in AHI at Week 52 with Zepbound was superior to placebo (-25.3 events/hour vs. -5.3 events/hour) ; align with ATS 2018 OSA weight-management guideline recommending anti-obesity pharmacotherapy in BMI ≥ 27 patients. - For MASH/NASH denials on Wegovy: provide specialist (hepatology/GI) attestation and documentation of stage F2 or F3 fibrosis confirmed by liver biopsy within 3 years, vibration-controlled elastography (VCTE), or MRE ; cite ESSENCE trial results. - For "not medically necessary" denials: reference ADA Standards of Care 2024 and AACE 2023 endorsing GLP-1 RAs and GLP-1/GIP agonists for chronic weight management with cardiometabolic comorbidities, and the AHA 2021 Scientific Statement on obesity and CVD risk.

## Why Cigna Denied This GLP-1 for Weight Loss: Prior Authorization Required

Cigna requires advance approval — called prior authorization (PA) — before covering GLP-1 medications prescribed for chronic weight management. A denial on this basis most commonly means the prescription was filled or processed without that approval in place, or that a PA request was submitted but not yet approved because required documentation was missing or incomplete.

## Why It Is Appealable

A prior-authorization denial is procedural in nature, not a final clinical determination. It does not mean Cigna has concluded the treatment is medically inappropriate — only that the administrative gate was not cleared. If your prescriber can document that your situation meets Cigna's coverage criteria, there is a strong basis to appeal and, in parallel, to resubmit a complete PA request.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full and fair review of any adverse benefit determination, including PA denials. Submit your internal appeal in writing within the timeframe stated on the denial notice.
• Expedited review: If waiting for standard review timelines would seriously jeopardize your health, request an expedited internal appeal. Cigna must respond on an accelerated schedule.
• External review: If the internal appeal is denied, you may escalate to independent external review under ACA §2719. The standard filing window is approximately four months from the denial notice date.

## Documentation to Gather

1. Diagnosis and clinical records: Chart notes documenting your obesity or overweight diagnosis and any obesity-related comorbidities your prescriber identified as relevant. 2. Medical-necessity letter: A detailed letter from your prescribing physician explaining the clinical rationale, why this medication is appropriate for you, and how you meet Cigna's published PA criteria for GLP-1 weight-loss therapy. 3. Prior treatment history: Documented evidence of previous weight-management attempts (dietary programs, behavioral counseling, other pharmacotherapy) with dates, durations, and outcomes, particularly any that Cigna's PA criteria require. 4. Cigna's PA criteria: Download Cigna's current published coverage policy or PA criteria for GLP-1 weight-loss agents from Cigna's medical policy library. Use these as a checklist. 5. Prescriber contact information: Ensure your prescriber's office is available to respond quickly to any Cigna peer-to-peer review requests.

## Criteria-Mapping Structure

Obtain the exact PA criteria from Cigna's published medical policy for this drug class. Create a numbered list of each requirement. For each one, write the specific chart fact, date, or document that satisfies it. This point-by-point correspondence is the single most effective element of a successful PA appeal because it eliminates ambiguity and prevents reviewers from overlooking evidence.